{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.98","upperLimit":"10.94","value":"8.15"},{"comment":"Here \"NA\" indicates that upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"8.61","upperLimit":"NA","value":"14.03"}]}],"title":"Time to Worsening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.81","upperLimit":"11.20","value":"5.59"},{"groupId":"OG001","lowerLimit":"2.20","upperLimit":"5.75","value":"3.75"}]}],"title":"Time to Improvement"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). Time to Worsening is defined as time interval (months) from randomization to first observation of deterioration. Worsening is defined as a decrease \\>= 3 points (on a 0-52 scale). Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. Improvement is defined as an increase \\>=3 points (on a 0-52 scale).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment Arm A (Ibrutinib + Venetoclax)"},{"description":"Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG001","title":"Treatment Arm B (Chlorambucil + Obinutuzumab)"}],"paramType":"MEDIAN","populationDescription":"The ITT analysis set included all randomized participants who were analyzed according to assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 2 years 10 months","title":"Time to Worsening and Time to Improvement as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score","type":"SECONDARY","unitOfMeasure":"Months"}